drugset / Trial / NCT03193203

Pharmacokinetics, Safety, and Tolerability Study of the Autoinjector and Pre-filled Syringe of SB4 in Healthy Male Subjects

NCT03193203

Phase 1 Completed 50 enrolled Samsung Bioepis Co., Ltd.
RandomizedCrossoverOpen-labelOther

Summary

The purpose of this study is to compare the pharmacokinetics, safety, and tolerability of the autoinjector and pre-filled syringe of SB4 in healthy male subjects.

Timeline

Start
2017-03-24
Primary completion
2017-08-07
Completion
2017-08-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Etanercept Protein / enzyme biologic 50 mg/ml

Indications

No indication recorded.